Atlas Trials

Verastem, Inc.

27 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Verastem, Inc.

RecordFirmDate
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (NCT07747506)Verastem, Inc.2026-08-03
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (NCT07659795)Verastem, Inc.2026-07-28
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer (NCT07659782)Verastem, Inc.2026-07-22
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer (NCT07644559)Verastem, Inc.2026-06-16
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (NCT07020221)Verastem, Inc.2025-06-24
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients (NCT06682572)Verastem, Inc.2024-10-30
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (NCT06072781)Verastem, Inc.2024-03-18
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (NCT05669482)Verastem, Inc.2023-03-22
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (NCT05375994)Verastem, Inc.2022-08-01
Food Effect of VS-6766 in Healthy Adult Subjects (NCT05187169)Verastem, Inc.2021-12-16
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (NCT04620330)Verastem, Inc.2020-12-31
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (NCT04625270)Verastem, Inc.2020-12-21

Track Verastem, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.